Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Not yet recruiting
Feeds
16710 items (16710 unread) in 74 feeds
Acinar Cell Carcinoma
(162 unread)
Acinic Cell Carcinoma
(75 unread)
Adenoid Cystic Carcinoma
(314 unread)
Adrenal Gland Cancer
(1378 unread)
Ampulla Of Vater
(181 unread)
Anal Cancer
(1549 unread)
Angiosarcoma
(437 unread)
Appendix Cancer
(353 unread)
Bile Duct Cancer
(1974 unread)
Brain and CNS
(2376 unread)
Carcinoid
(534 unread)
Endocrine/Neuroendocrine
(1850 unread)
Gall Bladder Cancer
(588 unread)
Hemangioendothelioma
(181 unread)
Hepatoblastoma
(339 unread)
Pancreas
(285 unread)
Phyllodes
(198 unread)
PMP and Mucinous Tumors
(197 unread)
Rhabdomyosarcoma
(625 unread)
Sarcoma
(3114 unread)
Trials - Gall Bladder Cancer (30 unread)
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Posted: January 11th, 2019, 3:00pm GMT
-
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer
Posted: January 8th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Drug: GS+Toripalimab
Sponsors: Shanghai Zhongshan Hospital; Shanghai Junshi Bioscience Co.,Ltd.; Shanghai OrigiMed Medical Technology Co., Ltd.
Recruiting -
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Posted: December 31st, 2018, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Drug: telotristat ethyl
Sponsor: Lexicon Pharmaceuticals
Not yet recruiting -
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
Posted: December 18th, 2018, 3:00pm GMT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Capecitabine
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Recruiting -
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Posted: December 11th, 2018, 3:00pm GMT
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
Intervention: Biological: mutation and signal pathway activation status analysis Drug: FORFIRINOX
Sponsors: Shanghai Jiao Tong University School of Medicine; Ruijin Hospital; RenJi Hospital; Eastern Hepatobiliary Surgery Hospital; Huashan Hospital
Recruiting -
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Posted: December 7th, 2018, 3:00pm GMT
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
Interventions: Biological: conventional chemotherapy(FORFIRINOX) combined with target agents; Biological: conventional chemotherapy(FORFIRINOX)
Sponsors: Shanghai Jiao Tong University School of Medicine; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital; RenJi Hospital; Eastern Hepatobiliary Surgery Hospital; Huashan Hospital
Recruiting -
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Posted: December 7th, 2018, 3:00pm GMT
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting -
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer
Posted: December 4th, 2018, 3:00pm GMT
Conditions: Gallbladder Diseases; Healthy
Intervention: Other: Benigh gallbladder diseases
Sponsor: Tongji Hospital
Not yet recruiting -
Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
Posted: November 5th, 2018, 3:00pm GMT
Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting -
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Posted: October 24th, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Resectable Pancreatic Cancer
Interventions: Drug: Pimonidazole; Procedure: Surgical Resection
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
Not yet recruiting -
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
Posted: October 11th, 2018, 2:00pm GMT
Condition: Gallbladder Carcinoma
Interventions: Drug: Apatinib; Drug: Tegafur
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting -
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy
Posted: September 17th, 2018, 2:00pm GMT
Conditions: Incidental Gallbladder Carcinoma; Biliary Tract Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Procedure: Oncologically radical margin-free (R0) resection; Drug: Adjuvant chemotherapy
Sponsors: Krankenhaus Nordwest; German Research Foundation
Not yet recruiting -
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
Posted: September 12th, 2018, 2:00pm GMT
Conditions: Liver Cancer; Pancreatic Cancer; Gastric Cancer; Esophageal Cancer; Colo-rectal Cancer; Gall Bladder Cancer; Biliary Tract Cancer
Interventions: Drug: Fluorouracil; Drug: Lederfolin; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Docetaxel; Drug: Cisplatin; Drug: Epirubicin; Drug: Gemcitabine; Drug: Nab paclitaxel
Sponsors: University of Pisa; Azienda Ospedaliero, Universitaria Pisana
Recruiting -
The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
Posted: August 20th, 2018, 2:00pm GMT
Conditions: Pancreas Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Other: Measurement of triceps skinfold thickness
Sponsor: Samsung Medical Center
Recruiting -
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Posted: July 31st, 2018, 2:00pm GMT
Conditions: Cancer of Pancreas; Cancer of Liver; Cancer of Rectum; Cancer of Colon; Cancer, Gall Bladder; Myeloma Multiple; Glioblastoma Multiforme
Interventions: Drug: Cannabidiol; Drug: Bortezomib; Drug: Leucovorin; Drug: 5-FU; Drug: Oxaliplatin; Drug: Bevacizumab; Drug: Irinotecan; Drug: Gemcitabine; Drug: Temozolomide
Sponsor: Leaf Vertical Inc.
Not yet recruiting -
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Stage I Gallbladder Cancer AJCC v8; Stage II Gallbladder Cancer AJCC v8; Stage IIA Gallbladder Cancer AJCC v8; Stage IIB Gallbladder Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8
Interventions: Drug: Capecitabine; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Emory University
Not yet recruiting -
Integrative Medicine for Chemotherapy-Induced Peripheral Neuropathy
Posted: September 25th, 2017, 2:00pm GMT
Condition: Chemotherapy-induced Peripheral Neuropathy
Interventions: Other: Acupuncture; Other: Multi-modality (Acupuncture "plus")
Sponsors: The Chaim Sheba Medical Center; Bnai Zion Medical Center; Lin Medical Center, Haifa; Carmel Medical Center
Recruiting -
Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenoc
Posted: August 31st, 2017, 2:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma
Interventions: Drug: PEGPH20; Drug: CIS; Drug: GEM; Drug: Atezolizumab
Sponsor: Halozyme Therapeutics
Recruiting -
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Posted: August 22nd, 2017, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting -
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
Posted: July 27th, 2017, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: Varlitinib; Drug: Capecitabine
Sponsor: Aslan Pharmaceuticals
Recruiting -
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Posted: June 28th, 2017, 2:00pm GMT
Conditions: Gallbladder Carcinoma; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Cobimetinib; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Recruiting -
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Posted: April 28th, 2017, 2:00pm GMT
Conditions: Radiation Therapy; Cancer; Cancer of Anus; Cancer of Bladder; Cancer of Cervix; Cancer of Colon; Cancer of Rectum; Cancer of Esophagus; Cancer of Gallbladder; Cancer of Liver; Cancer of Ovary; Cancer of Pancreas; Cancer of Prostate; Cancer of Kidney and Renal Pelvis; Cancer of Stomach; Cancer of Testis; Cancer of Uterus; Cancer of Uterus and Cervix; Cancer of Kidney
Intervention:
Sponsors: DxTerity Diagnostics; National Cancer Institute (NCI)
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Posted: March 28th, 2017, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: Varlitinib; Drug: Capecitabine; Drug: Placebo (for Varlitinib)
Sponsor: Aslan Pharmaceuticals
Recruiting -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 5th, 2016, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting -
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
Posted: August 16th, 2016, 2:00pm GMT
Condition: Gall Bladder Cancers
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Radiation: Chemoradiation; Procedure: PETCECT; Procedure: Laparoscopy
Sponsor: Tata Memorial Hospital
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Posted: November 19th, 2014, 3:00pm GMT
Conditions: Breast Cancer; Colon Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastrointestinal Cancer; Liver and Intrahepatic Biliary Tract Cancer; Lung Cancer; Metastatic Cancer; Pancreatic Cancer; Rectal Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: radionuclide imaging; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: pharmacological study; Drug: Cu 64 anti-CEA monoclonal antibody M5A IV
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting -
Integrated Cancer Repository for Cancer Research
Posted: December 16th, 2013, 3:00pm GMT
Conditions: Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; GIST; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; CNS Tumor; CNS Cancer; Mesothelioma; Breastcancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer
Intervention:
Sponsor: University of Nebraska
Recruiting -
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Posted: March 11th, 2011, 3:00pm GMT
Conditions: Non-GI Cancers; Cancer of Gastrointestinal Tract; Gastrointestinal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting